Publication date: May 23, 2025
IgA antibodies are involved in mucosal immunity and eliminate pathogens immediately at the point of entry. Vaccine-induced IgA antibodies could contribute to an additional layer of protection against SARS-CoV-2 for infection prone cancer patients. This might be particularly relevant for cancer patients as they mount reduced IgG antibody titers after dual-dose BNT162b2 COVID-19 vaccination and even lower responses after double-dose ChAdOx1 vaccination, compared to healthy individuals. However, data on vaccine-induced IgA antibodies are scarce, especially in cancer patients. This study compares SARS-CoV-2 anti-S1 IgA antibodies after dual-dose BNT162b2 vs ChAdOx1 vaccination in cancer patients. SARS-CoV-2 anti-S1 IgA antibodies were quantified in serum samples collected 7 days after second vaccination dose (N=213) (IEQ-CoVS1RBD-IgA-1-RB ELISA kit, RayBiotech) and analyzed with colorimetric detection. Additionally correlations with different aspects of humoral immunity were assessed (neutralizing and IgG antibodies). Significant lower anti-S1 IgA antibody titers were reported in cancer patients after dual-dose ChAdOx1 compared to BNT162b2 vaccination. Moreover, cancer patients that received dual-dose BNT162b2 vaccination had a significant 16. 44 fold increased chance to mount detectable IgA antibodies compared to patients receiving ChAdOx1 vaccination. These findings highlight the potential role of boosters or alternative strategies to sustain mucosal immunity.
| Concepts | Keywords |
|---|---|
| Bnt162b2 | cancer patients |
| Colorimetric | COVID-19 vaccination |
| Covid | IgA antibodies |
| Raybiotech | SARS-CoV-2 |
| Vaccines |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | cancer |
| disease | MESH | infection |
| disease | MESH | COVID-19 |
| disease | IDO | role |